GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Float Percentage Of Total Shares Outstanding

IPHA (Innate Pharma) Float Percentage Of Total Shares Outstanding : 88.36% (As of May. 05, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Innate Pharma's float shares is 81.43 Mil. Innate Pharma's total shares outstanding is 92.16 Mil. Innate Pharma's float percentage of total shares outstanding is 88.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Innate Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Innate Pharma's Institutional Ownership is 0.15%.

Innate Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Innate Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=81.43/92.16
=88.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
XPAR:NANO XPAR:GNFT XPAR:OSE XPAR:ALCLS XPAR:MAAT XPAR:DBV XPAR:TNG XPAR:ADOC XPAR:ALSEN XPAR:ABNX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
IPHYF:USA 0EVI:UK IPH:France
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.